21 June 2021 ORYZON to present new clinical data and corporate updates at international conferences in June and July
15 June 2021 ORYZON announces FDA approval of IND for PORTICO, a Phase IIb trial with vafidemstat in Borderline Personality Disorder
11 June 2021 ORYZON presents iadademstat ALICE 30-month data at EHA-2021, confirming positive and robust efficacy in combination with azacitidine in AML
13 May 2021 ORYZON to present new clinical data and corporate updates at international conferences in May and June
6 April 2021 ORYZON starts preclinical collaboration on autism with the Seaver Autism Center at Mount Sinai
29 March 2021 ORYZON enrolls first patient in PORTICO, a Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder
24 March 2021 ORYZON publishes vafidemstat first-in-human clinical trial manuscript in CNS Drugs journal